Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Nicholas Kozauer"'
Autor:
Shailly Mehrotra, Atul Bhattaram, Kevin Krudys, Michael Bewernitz, Ramana Uppoor, Mehul Mehta, Tao Liu, Philip Sheridan, Norman Hershkowitz, Nicholas Kozauer, Eric Bastings, Billy Dunn, Angela Yuxin Men
Publikováno v:
Clinical Pharmacology & Therapeutics. 112:853-863
The US Food and Drug Administration (FDA) has concluded that the efficacy of drugs approved for the treatment of partial onset seizures (POS) in adults can be extrapolated to pediatric patients 1 month of age and above and that independent efficacy t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2efcf53ec44dc956f39efc84fc5b8745
https://doi.org/10.1002/cpt.2681
https://doi.org/10.1002/cpt.2681
Autor:
Pangaja Paramsothy, Deborah J. Fox, Kristin M Conway, Gregory Haber, Nicholas E. Johnson, Venkatesh Atul Bhattaram, Swamy Venkatesh, Russell J. Butterfield, Han C Phan, Hobart Rogers, Nicholas Kozauer, Maureen K. Galindo, Natalie Street, Nedra Whitehead, Joyce Oleszek, Xiang Ling, Anindya Roy, Shree Pandya, Dennis J. Matthews, Paul A. Romitti, Katherine A. James, Emma Ciafaloni
Publikováno v:
Muscle Nerve
BACKGROUND Quantifying associations between genetic mutations and loss of ambulation (LoA) among males diagnosed with childhood-onset dystrophinopathy is important for understanding variation in disease progression and may be useful in clinical trial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9433c27b5893865213c85fa691110ba
https://pubmed.ncbi.nlm.nih.gov/33150975
https://pubmed.ncbi.nlm.nih.gov/33150975
Autor:
Mark S. Forman, Maria C. Carrillo, Christopher Randolph, David S. Knopman, John R. Sims, David S. Miller, Lisa J. Bain, Maria Isaac, Nicholas Kozauer, Niklas Mattsson, Ronald C. Petersen, Susan DeSanti, Eric E. Smith, James Hendrix, Gil D. Rabinovici
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer's & dementia (New York, N. Y.), vol 3, iss 1
Alzheimer's & dementia (New York, N. Y.), vol 3, iss 1
Dementia is often characterized as being caused by one of several major diseases, such as Alzheimer's disease (AD), cerebrovascular disease, Lewy body disease, or a frontotemporal degeneration. Failure to acknowledge that more than one entity may be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ae5a8899349e9299f420d88fedbbfc
http://europepmc.org/articles/PMC5651346
http://europepmc.org/articles/PMC5651346
Autor:
Sarah Dubrava, Eric Siemers, Michelle Stewart, David S. Miller, H. Robert Brashear, Yeates Conwell, Nicholas Kozauer, Larry Alphs, Phillip B. Chappell, Rachel Schindler, Kristine Yaffe, Ni A. Khin, Dean M. Hartley
Publikováno v:
Alzheimer's & Dementia : Translational Research & Clinical Interventions
Alzheimer's & dementia (New York, N. Y.), vol 2, iss 1
Alzheimer's & dementia (New York, N. Y.), vol 2, iss 1
Introduction Better understanding of suicide risk and its management in older adults with cognitive impairment and/or dementia remain significant unmet public health needs. Urgency to address them derives from concern that CNS treatments for dementia
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa9e57429b21e4bb5094da35607a2184
http://europepmc.org/articles/PMC5644272
http://europepmc.org/articles/PMC5644272
Autor:
Nicholas Kozauer, Karl Broich
Improvement of cognition by medicinal products is an accepted concept by regulatory agencies. In dementing conditions such as Alzheimer’s disease, improvement of cognition or slowing its deterioration is essential for approval, particularly in earl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::58834a373f8f3955a0118596f2da941a
https://doi.org/10.1093/med/9780190214401.003.0016
https://doi.org/10.1093/med/9780190214401.003.0016
Autor:
Nicholas Kozauer, Russell Katz
Publikováno v:
New England Journal of Medicine. 368:1169-1171
The focus of drug development in Alzheimer's disease has increasingly been on earlier disease stages, before overt dementia, when it is difficult to assess cognitive impairment. The FDA has now developed guidance for the design and execution of relev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a23b9cf07349540a476105dab6d2835
https://doi.org/10.1056/nejmp1302513
https://doi.org/10.1056/nejmp1302513
Autor:
Russell Katz, Nicholas Kozauer
Publikováno v:
The New England journal of medicine. 369(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5ce238e2b098a6f0cf0fdfb5de131c9
https://pubmed.ncbi.nlm.nih.gov/23863070
https://pubmed.ncbi.nlm.nih.gov/23863070
Autor:
Constantine G. Lyketsos, James J. Pekar, Michael George, Marilyn S. Albert, Michelle M. Mielke, Susumu Mori, Nicholas Kozauer, Karen Bandeen-Roche, Jaimie Toroney, Gary Chan, Peter vanZijl
Publikováno v:
Alzheimer's & Dementia. 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::594b3d8604cac6e68586740aa50fc501
https://doi.org/10.1016/j.jalz.2007.04.264
https://doi.org/10.1016/j.jalz.2007.04.264
Autor:
Nicholas Kozauer, John Siberski
Publikováno v:
Journal of Psychiatric Practice. 11:216
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::03eabd35b6450a2820257e45c43fd9f4
https://doi.org/10.1097/00131746-200505000-00011
https://doi.org/10.1097/00131746-200505000-00011